Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kalvista Pharmaceuticals Inc (NQ: KALV )

5.190 -0.120 (-2.26%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,529
Open 5.320
Bid (Size) 4.700 (1)
Ask (Size) 5.390 (2)
Prev. Close 5.310
Today's Range 5.050 - 5.320
52wk Range 4.120 - 17.34
Shares Outstanding 24,602,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-62.69%
-62.69%
1 Month
+3.59%
+3.59%
3 Month
-68.88%
-68.88%
6 Month
-41.62%
-41.62%
1 Year
-65.58%
-65.58%

More News

Read More
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Expert Ratings for KalVista Pharma
Via Benzinga
Where KalVista Pharma Stands With Analysts
Via Benzinga
Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?
Via InvestorPlace
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients
Via Benzinga
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67%
Via Benzinga
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
Via Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
Via Investor's Business Daily
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
Via Benzinga
FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
US Stocks Open Higher As Dow Jumps 550 Points
Via Benzinga
Why Kalvista Pharmaceuticals Shares Are Down Over 50%
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.